CCL2 is a Potent Regulator of Prostate Cancer Cell Migration and Proliferation  by Loberg, Robert D. et al.
CCL2 is a Potent Regulator of Prostate Cancer Cell Migration
and Proliferation1
Robert D. Loberg*,y, LaShon L. Day*, Jason Harwood*, Chi Ying*, Lauren N. St. John*, Ryan Giles*,
Chris K. Neeley* and Kenneth J. Pienta*,y
*Department of Urology, University of Michigan Urology Center, Ann Arbor, MI, USA; yDepartment of Internal
Medicine, University of Michigan, Ann Arbor, MI, USA
Abstract
Tumor cells in the bone interact with the microenviron-
ment to promote tumor cell survival and proliferation,
resulting in a lethal phenotype for patients with
advanced prostate cancer. Monocyte chemoattractant
protein 1 (CCL2) is a member of the CC chemokine
family and is known to promote monocyte chemotaxis
to sites of inflammation. Here we have shown that
human bone marrow endothelial (HBME) cells secrete
significantly higher levels of CCL2 compared to human
aortic endothelial cells and human dermal micro-
vascular endothelial cells. Furthermore, we demon-
strate that CCL2 is a potent chemoattractant of prostate
cancer epithelial cells, and that stimulation of PC-3 and
VCaP cells resulted in a dose-dependent activation
of PI3 kinase/Akt signaling pathway. Activation of the
PI3 kinase/Akt pathway was found to be vital to the
proliferative effects of CCL2 stimulation of both PC-3
and VCaP cells. Additionally, CCL2 stimulated the
phosphorylation of p70-S6 kinase (a downstream target
of Akt) and induced actin rearrangement, resulting in a
dynamic morphologic change indicative of microspike
formation. These data suggest that bone marrow
endothelial cells are a major source of CCL2, and that
an elevated secretion of CCL2 recruits prostate cancer
epithelial cells to the bone microenvironment and
regulates their proliferation rate.
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Introduction
The predominance of prostate cancer metastasis to the
bone has been well documented from three independent
autopsy series and has been reported to occur with > 85%
frequency on patients with advanced hormone-refractory
prostate cancer [1]. However, the mechanisms responsible
for the prevalence of osseous lesions in men with prostate
cancer remain unclear. Metastasis is a process that is de-
fined by a series of sequential steps resulting in end organ
tumor metastasis through a migratory pattern that appears
to be directed, specific, and predictable [1]. Onemechanism
that has been proposed to explain the enhanced frequency
of bone metastases in prostate cancer is preferential adhe-
sion to the bone marrow endothelium [2]. However, simply ad-
hering to the endothelial wall is not sufficient to invade an organ;
thus, some cancer cells must acquire the ability to migrate from
the luminal side of the endothelial cells into the surrounding
tissue in response to chemotactic molecules released by stro-
mal cells. Several chemokines, including stromal cell–derived
factor 1 (SDF-1/CXCL12) and, recently, CCL2 [3–5], have
been shown to promote chemotactic migration of cancer cells
(prostate for SDF-1 [4] and myeloma for CCL2 [5]). CCL2 is a
member of the CCb chemokine family and was originally
known to promotemonocyte andmacrophagemigration to sites
of inflammation [6,7].
CCL2 has previously been shown to be an important deter-
minant of macrophage and monocyte infiltration in breast,
cervix, and pancreatic carcinomas [8]. Recent studies have
demonstrated that CCL2 localizes to tumor epithelial cells [9],
and that the levels of CCL2 expression have been correlated
with the involvement of lymphocyte and macrophage localiza-
tion in secondary sites of tumor formation [10]. There is growing
evidence to suggest that CCL2may act directly on the epithelial
cells of several human carcinomas and may regulate the
migration and invasive properties of tumor cells, resulting in
enhanced metastatic potential. Youngs et al. [11] demonstrated
a dose-dependent migratory response of breast cancer cells
to increasing concentrations of exogenous CCL2. Additionally,
CCL2 expression has been shown to correlate with progres-
sion in pancreatic cancer [12] and breast cancer [13]. Here we
describe a role for CCL2 in prostate cancer migration and
proliferation as a mechanism for increased bone metastases.
Accordingly, we hypothesized that CCL2 is a novel potent
regulator of prostate cancer migration and proliferation at the
site of the bone microenvironment.
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Human recombinant CCL2 (hrCCL2) and anti-CCL2 anti-
body were obtained from Chemicon International (Temecula,
CA); anti–phospho AktSer473, anti-Akt, anti-GSK3b, anti–
phospho GSK3a/b, anti–p70-S6 kinase, and anti–phospho
p70-S6 kinase were obtained from Cell Signaling (Beverly,
MA); and all other reagents were obtained from Sigma-Aldrich
(St. Louis, MO).
Cell Culture
PC-3 prostate cancer, human aortic endothelial cells
(HAECs), and human dermal microvascular endothelial cells
(HDMVECs) were obtained from ATCC (Manassas, VA) and
passaged under appropriate growth conditions. VCaP pros-
tate cancer and human bone marrow endothelial (HBME)
cells were a kind gift from Dr. Kenneth J. Pienta (University
of Michigan, Ann Arbor, MI). PC-3 cells were maintained in
RPMI 1640 + 10% fetal calf serum (FCS) (Invitrogen Corp.,
Carlsbad, CA). HAECs and HDMVECs were maintained in
EGM + 5% FCS, whereas VCaP and HBME cells were main-
tained in DMEM + 10% FCS (Invitrogen Corp.). Cells were
passaged by trypsinization using 1 trypsin + EDTA (Invi-
trogen Corp.) and resuspended in appropriate growth media.
Cytokine Antibody Array
Normal vertebral tissue and tumor vertebral tissue were
collected from a patient with advanced hormone-refractory
prostate cancer, in accordance with the rapid autopsy series
conducted at the University of Michigan. Tissue specimens
weresnap frozen in liquid nitrogenandpulverizedwith amortar
and pestle. Crushed tissue was resuspended in RIPA buffer
(50mMTris–HCl, pH 7.4; 1%NP-40; 150mMNaCl; and 1mM
EDTA) containing protease inhibitors (1 mg/ml aprotinin, leu-
peptin, and pepstatin A; 1 mM PMSF; 1 mM NaF; and 1 mM
Na3VO4). Lysates were pulse-sonicated at 40% duty cycle for
5 seconds, and protein lysates were collected by centrifuga-
tion at 13,000 rpm for 15 minutes at 4jC. Protein lysates were
diluted, and cytokine arrays were performed according to the
manufacturer’s instructions (RayBiotech, Inc., Norcross, GA).
CCL2 Enzyme-Linked Immunosorbent Assay (ELISA)
Cells were plated in six-well plates and grown to 80%
confluency in appropriate growth media. Cells were then
washed with serum-free RPMI 1640 or DMEM supplemented
with 1% penicillin and streptomycin. Cells were incubated in
serum-free media for 24 hours, and the conditioned medium
from each well was collected and stored at 80jC until use.
The level of CCL2 in cell culture supernatants was deter-
mined with Quantikine human CCL2 sandwich ELISA kit
(R&D Systems, Minneapolis, MN), according to the protocol
supplied by the manufacturer.
Fluorescence-Based Migration Assay
Cell migration was assessed using Innocyte Cell Migration
Assay (Calbiochem, Inc.), following the manufacturer’s
instructions. Briefly, increasing concentrations of CCL2 (1–
100 ng/ml) in the presence and absence of CCR2 inhibitors or
neutralizing antibodies were added to the lower chamber of a
96-well plate. Cells were harvested by 0.5 mM EDTA release
and resuspended at 2.5  105 cells/ml in serum-free media.
A total of 2.5  104 cells was added to the upper chamber
and allowed to migrate through the membrane with 8-mm
pores for 24 hours at 37jC and 5% CO2 atmosphere. Cells
that migrated through the membrane were detached and
labeled with calcein AM, and fluorescence was measured
using a fluorescent plate reader with an excitationwavelength
of 485 nm and an emission wavelength of 520 nm. The ex-
periment was repeated in triplicate, and each conditioned ex-
periment was performed in quadruplicate.
Western Blot Analysis
Cells were lysed in RIPA buffer (50 mM Tris–HCl, pH 7.4;
1% NP-40; 150 mM NaCl; 1 mM EDTA; 1 mM PMSF; 1 mM
Na3VO4; 1mMNaF; 1 mMokadaic acid; and 1 mg/ml aprotinin,
leupeptin, and pepstatin). Proteins were separated under
reducing conditions by sodium dodecyl sulfate–polyacryl-
amide gel electrophoresis and transferred onto nitrocellulose
membrane. The membranes were blocked with 5% milk in
0.1% Tween in Tris-buffered saline for 1 hour at room tem-
perature. They were incubated overnight at 4jC with primary
antibodies. Membranes were washed thrice before incuba-
tion with horseradish peroxidase–conjugated secondary
antibodies (Cell Signaling) for 1 hour at room temperature.
Protein expression was visualized by ECL chemilumines-
cence (Promega, Madison, WI) and quantitated using Image
J software (NCI, Bethesda, MD).
Immunofluorescence
PC-3 cells were plated on glass coverslips and serum-
starved for 2 hours before stimulation. Cells were stimulated
with CCL2 (100 ng/ml) for 30 minutes in the presence or
absence of identified inhibitors. Stimulation with SDF-1
(200 ng/ml) for 30 minutes was used as a positive control.
Cells were fixed in methanol-free 3.7% paraformaldehyde
for 10 minutes at room temperature then permeabilized with
0.5% Triton X-100 for 5 minutes at room temperature. Cells
were rinsed twice with PBS and incubated for 30 minutes at
room temperature with 3% bovine serum albumin (BSA) in
PBS + 0.05% Tween 20 to prepare cells for staining. Cells
were incubated with Phalloidin AlexaFluor568 (Molecular
Probes, Inc., Carlsbad, CA) at a 1:40 dilution in BSA solu-
tion to label actin. Cells were washed and mounted on
coverslips with Pro-Long Antifade containing DAPI (Molec-
ular Probes, Inc.), following the manufacturer’s instructions.
Immunofluorescence was visualized using a multiphoton
laser scanning microscope, consisting of a Mai Tai Broad-
band Ti:Sapphire laser (Spectra-Physics, Mountain View,
CA) (tunable between 710 and 990 nm) and a modified Olym-
pus Fluoview 300 confocal microscope (Olympus, Center
Valley, PA) with long working-distance water-immersion infra-
red objectives. Images were captured with a 60 objective
(zoom, 2), 800-nm excitation wavelength, and 605- and
520-nm centered emission filters.
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Proliferation Assay
Cells were seeded at a density of 4  103 cells/well in a
six-well plate with complete media. Twenty-four hours after
seeding, the medium was replaced with serum-free me-
dium supplemented with increasing concentrations of CCL2
(1–100 ng/ml) in the presence or absence of LY294002
(1 mM). Cell growth was determined at 24, 48, 72, and
96 hours after seeding using the WST-1 assay (Pierce Bio-
tech, Rockford, IL), following the manufacturer’s instructions.
Real-Time RT-PCR
Cells were serum-starved for 24 hours before RNA isola-
tion. Total RNA was isolated from cell lines using Trizol (Invi-
trogen Corp.), following the manufacturer’s specifications.
Purified RNA (5 mg) was converted to cDNA using Super
Script II reverse transcriptase (Invitrogen Corp.), following
the manufacturer’s instructions, and used for gene expres-
sion analysis by real-time PCR using an ABI Prism 7900HT
(Applied Biosystems, Foster City, CA) thermocycler. Primers
and probes were purchased from Applied Biosystems, Inc.,
and used with TaqMan Universal PCR Master Mix (Applied
Biosystems), No AmpErase UNG. GAPDH was used as an
internal control to normalize and compare each sample.
Cycle conditions for real-time PCR were 95jC (15 seconds),
60jC (1 minute), and 72jC (1 minute) for 40 cycles. The
threshold cycle number for each sample was normalized to
GAPDH for that sample and expressed on a log scale relative
to GAPDH expression.
Statistics
Data were analyzed with GraphPad Prizm software. One-
way analysis of variance was used with Bonferroni’s post hoc
analysis for comparison between multiple groups. Student’s
t test was used for comparison between two groups. Signifi-
cance was defined as P < .05.
Results
Identification of CCL2 Expression in the Tumor–Bone
Microenvironment
Identification of the prominent cytokines and growth fac-
tors involved in the tumor–bone microenvironment is essen-
tial to the understanding of prostate cancer metastasis. We
collected specimens from three patients diagnosed with
prostatic adenocarcinoma (Table 1). Sites of metastasis were
identified by gross examination, and tissue samples were
collected and snap frozen for analysis. Tumor and normal
(adjacent to tumor) bone specimens were collected from
vertebral lesions and processed for total protein lysates.
Analysis of cytokine and growth factor expression was
performed using cytokine antibody arrays from RayBiotech,
Inc. A representative cytokine array demonstrates that sev-
eral cytokines were upregulated in the tumor–bone micro-
environment, compared to the normal (adjacent to tumor)
bone microenvironment (Figure 1A). In particular, monocyte
chemoattractant protein 1 (CCL2) was upregulated four-fold
in the tumor microenvironment compared to that in the
normal microenvironment (Figure 1B).
Identification of the Source of CCL2 from Constituents
of the Bone Microenvironment
CCL2 is known to be a potent stimulator of monocyte and
macrophage migration to sites of inflammation [7]. To identify
a role of CCL2 in prostate cancer metastasis, CCL2 secretion
was determined by ELISA from PC-3, VCaP, HBME, osteo-
blasts, and NIH 3T3 L1 adipocytes. Interestingly, prostate
cancer cells were not a significant source of CCL2; however,
HBME cells secreted significantly more CCL2 compared to
the other cell lines analyzed (PC-3, 2.435 ± 0.123 pg/ml;
VCaP, 21.037 ± 3.213 pg/ml; HBME, 1269.083 ± 26.281 pg/
ml; OB, 4.32 ± 1.85 pg/ml; adipocytes, 18.398 ± 3.874 pg/ml;
mean ± SD) (Figure 2A). Next, the secretion of CCL2 from
different endothelial cell lines was compared to assess the
specificity of HBME cells as a significant source of CCL2.
HAECs and HDMVECs were used for comparison. HBME
cells secreted significantly higher levels of CCL2 compared to
HAECs and HDMVECs (HBME, 805.26 ± 29.81 pg/ml;
HAECs, 10.12 ± 3.70 pg/ml; HDMVECs, 21.86 ± 8.61 pg/ml;
mean ± SD) (Figure 2B). To identify CCL2 as an important
chemotactic factor secreted by HBME cells that induces
prostate cancer cell migration, cells were placed in amodified
Boyden chamber. The conditionedmedium (24 and 48 hours)
from HBME cells was used as chemoattractant, and PC-3
cell migration was measured after a 24-hour period. The
conditioned medium from HBME cells stimulated the migra-
tion of PC-3 cells, and the migration was inhibited by the
presence of an anti-CCL2 neutralizing antibody (PC-3: SFM,
164.6 ± 8.92; CM24, 308.4 ± 54.46; CM48, 481.2 ± 31.36;
CM24 + anti-CCL2, 155.6 ± 22.35; CM48 + anti-CCL2,
229.3 ± 22.35; mean ± SD) (Figure 2C).
Effects of CCL2 on Prostate Cancer Cell Migration
Migration is an essential step in metastatic cascade and is
dependent on the reorganization of the actin cytoskeleton.
The majority of data suggests that migration is regulated, in
part, by chemotactic gradients that stimulate the recruitment
of tumor cells to sites of metastases. In prostate cancer,
Table 1. Patient Information for Specimens Retrieved and Analyzed by Cytokine Antibody Array.
Patient Age on Autopsy
(years)




1 77 4 + 4 = 8 T2c 1.54 RT, H, C +
2 73 3 + 4 = 7 NA 5.5 RT, H, C +
3 70 4 + 5 = 9 T3 NA RP, H, C +
NA, not available; RT, radiation therapy; RP, radical prostatectomy; H, hormone therapy; C, chemotherapy.
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SDF-1 has been postulated as an important chemotactic
factor that stimulates prostate cancer cell migration through
activation of the CXCR4 receptor [4]. To further our under-
standing of the role of CCL2 in prostate cancer cell migration,
we used a 96-well migration assay with increasing con-
centrations of hrCCL2 as chemoattractant. PC-3 and VCaP
cells migrated in a dose-dependent manner toward hrCCL2
(PC-3: control, 44.62 ± 3.83; 1 ng/ml, 83.53 ± 2.981; 10 ng/ml,
142.2 ± 2.678; 100 ng/ml, 248.1 ± 0.761; VCaP: control,
116.4 ± 2.529; 1 ng/ml, 130.6 ± 2.145; 10 ng/ml, 176.1 ±
9.051; 100 ng/ml, 296.5 ± 2.681; mean fluorescence ± SD)
(Figure 3, A and C, respectively). The dose-dependent
migration of both PC-3 (Figure 3A) and VCaP (Figure 3C)
was attenuated by RS-102895, a CCR2b receptor antagonist
(Figure 3, A and C, respectively). CCL2-induced migration
was partially attenuated with the presence of an anti-CCR5
neutralizing antibody (Figure 3, A and C). Furthermore, the
migration of both PC-3 and VCaP cells to CCL2 at all
concentrations was attenuated by the administration of
anti–human CCL2 and anti–mouse CCL2/JE neutralizing
antibodies (Figure 3, B and D).
CCL2 Induces Akt Activation in PC-3 and VCaP Cells
CCL2 has been shown to induce the activation of the PI3
kinase/Akt signaling pathway [14]. To determine whether the
CCL2 stimulation of PC-3 and VCaP cells induces similar
signaling pathways, PC-3 and VCaP cells were stimulated
with a supraphysiological dose of CCL2 (100 ng/ml) for
various time points indicated. CCL2 induced Akt phos-
phorylation, as measured by immunoblot analysis in a time-
dependent fashion, in both VCaP and PC-3 cells, with a
maximal activation at 30 minutes (Figure 4, A and C).
Furthermore, PC-3 and VCaP cells were stimulated with
increasing concentrations of CCL2 (0.1–100 ng/ml) for
30 minutes. CCL2 stimulated Akt phosphorylation in a
dose-dependent fashion in PC-3 and VCaP cells (Figure 4,
B and D). Furthermore, stimulation of PC-3 cells with CCL2
Figure 2. ELISA of CCL2 release. (A) Two prostate cancer cell lines (PC-3
and VCaP), bone marrow endothelial cells (HBME), osteoblasts (OB), and
adipocytes (NIH 3T3 L1) cells were plated in six-well plates. Conditioned
medium was collected after 24 hours, and CCL2 levels were analyzed with
ELISA. (B) Aortic endothelial cells (HAECs), microvascular endothelial cells
(HDMVECs), and bone marrow endothelial cells (HBME) were plated in six-
well plates, and conditioned medium was collected after 24 hours. CCL2
concentrations are reported as picograms per milliliter per 100,000 cells, and
the data are presented as mean ± SD. *P < .001. (C) Conditioned medium
was collected from HBME cells after 24 or 48 hours and placed in the lower
chamber of the Innocyte Cell Migration Assay. PC-3 cells were plated in the
upper chamber, and cell migration was determined after 24 hours in the
presence of an anti-CCL2 blocking antibody. *P < .001 vs control; +P < .001
vs HBME CM24; **P < .001 vs HBME CM48.
Figure 1. Representative cytokine antibody arrays comparing normal (A)
versus tumor (B) microenvironments. Arrays demonstrate the upregulation of
CCL2 (boxed in area; replicates of two) in the normal bone (A) compared to
that in the tumor–bone (B) microenvironments. (C) Graphical representation
of CCL2 expression by cytokine antibody array analysis in normal adrenal,
adrenal tumor, normal liver, liver tumor, normal bone, and bone tumor (n = 3;
three patients from the rapid autopsy program at the University of Michigan).
Data are represented as mean ± SD. *P < .001.
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at 100 ng/ml induced p70-S6 kinase phosphorylation, but
had no effect on GSK3a/b phosphorylation, both of which are
downstream targets of Akt (Figure 4E ).
Effects of CCL2 on Prostate Cancer Cell Proliferation
through Activation of PI3 Kinase/Akt
Activation of PI3 kinase/Akt is known to be in favor of the
proliferative signaling pathway [15], and previous evidence
has shown that CCL2 stimulates the proliferation of macro-
phages through a PI3 kinase/Akt–dependent mechanism
[16]. To assess the effects of CCL2 on prostate cancer cell
proliferation, PC-3 and VCaP cells were stimulated with in-
creasing concentrations of CCL2 for 24, 48, 72, and 96 hours
in the presence of LY294002 (1 mM), a PI3 kinase inhibitor.
Both PC-3 and VCaP cells demonstrated enhanced prolifer-
ation in a dose-dependent fashion in response to CCL2 over
the 96-hour proliferation assay (solid lines, Figure 5,A andB).
The effects of CCL2 onPC-3 and VCaP cell proliferation were
attenuated by the addition of LY294002 (1 mM) during the
96-hour assay (dashed lines, Figure 5, A and B).
Differential Expression of CCL2 Receptors in Prostate
Cancer Cell Lines
To determine the mechanism of action of CCL2 on pros-
tate cancer cells, the differential mRNA expression of CCR2,
the high-affinity receptor for CCL2, was quantified by real-
time PCR and normalized to GAPDH levels expressed in a
panel of prostate cancer cell lines. The results are displayed
using the cycle threshold method previously described [17].
CCR2 was variably expressed in RWPE-1, PC-3, VCaP,
DU145, LNCaP, C4-2B, and DUCaP. PC-3 and VCaP had
the highest levels of expression (Table 2).
CCL2 Induces Actin Reorganization in PC-3 Cells
Change in the organization of the actin cytoskeleton is an
essential step in the migratory and proliferative phenotype of
most cells and is known to be linked to G protein–coupled
receptors [11]. CCR2 is a G protein–coupled receptor and
has been shown to regulate the actin cytoskeleton, resulting
in a phenotypic change in migration of B cells [18]. Addi-
tionally, p70-S6 kinase has been shown to regulate actin
polymerization and to colocalize with actin at the leading
edge during filapodial extension [19]. We assessed the ability
of CCL2 to stimulate alteration in the actin cytoskeleton in
PC-3 cells. Immunofluorescence revealed morphologic
changes consistent with actin rearrangement and the for-
mation of ‘‘finger-like’’ projections or microspikes after
30-minute stimulation with CCL2 (10 ng/ml) compared to
control cells (Figure 6, A and B). Furthermore, coincubation
of CCL2 (10 ng/ml) with an anti-CCL2 (2 mg/ml) neutralizing
Figure 3. CCL2 is a chemoattractant for prostate cancer cells and stimulates cell migration. Prostate cancer cell migration in response to CCL2 was also assessed
with recombinant human CCL2 (1–100 ng/ml) in (A) PC-3 and (C) VCaP cells. CCR2 receptor inhibitor (1 M) and an anti-CCR5 neutralizing antibody (10 g/ml)
were used to identify the receptor involved. SDF-1 (200 ng/ml) was used as a positive control for PC-3 migration. Data are presented as mean ± SD. (B) PC-3 and
(D) VCaP cells’ dose-dependent migration in hrCCL2 was attenuated by neutralizing anti-CCL2 antibodies (4 g/ml) and anti –mouse CCL2/JE antibody (2 g/ml).
Anti-hIgG and anti-gIgG were used as antibody controls. SDF-1 (200 ng/ml) was used as a positive control. *P < .01 vs untreated; +P < .05 vs CCL2 (1 ng/ml);
#P < .01 vs CCL2 (10 ng/ml); **P < .01 vs CCL2 (100 ng/ml).
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antibody attenuated the actin reorganization and formation of
finger-like projections (Figure 6C).
Discussion
Recognition of prostate cancer metastasis to the bone as a
lethal phenotype leads to the design of new targeted thera-
pies directed at both the cancer cells and the bone micro-
environment. Tumor cells in the bone interact with the
extracellular matrix, stromal cells, osteoblasts, osteoclasts,
and endothelial cells to coordinate a sophisticated series of
interactions to promote tumor cell survival and proliferation,
leading to morbidity and mortality for patients with advanced
prostate cancer [20,21]. There is growing evidence sup-
porting the hypothesis that cytokines and chemokines re-
leased in the local microenvironment promote metastasis,
tumor cell proliferation, and tumor growth in a specific coor-
dinated mechanism [4]. Here we demonstrate an important
role of CCL2, a member of the CC chemokine family, in the
pathogenesis of prostate cancer skeletal metastases.
Utilizing tissue procured during the rapid autopsy program
at the University of Michigan, a comparison was made
between cytokine and chemokine expression in the micro-
environment of bone metastatic lesions and normal/adjacent
bone from three patients with advanced metastatic disease
using a cytokine/growth factor antibody array (Figure 1). The
most upregulated chemokine (more than a four-fold increase)
in the tumor–bonemicroenvironment was identified as CCL2
(Figure 1C). A number of other cytokines were elevated by
more than two-fold in the tumor–bone microenvironment
when compared to the normal/adjacent bone (EGF, FGF-6,
IGFBP-1, IGFBP-2, IL-3, IL-4, IL-6, MDC, MIG, TGFb1,
TGFb3, TNF-b, and angiogenin). Furthermore, CCL2 ex-
pression in the tumor microenvironment was specifically
elevated in bone lesions compared to its expression in soft
tissue lesions, suggesting that CCL2 may be an important
chemokine in prostate cancer bone biology. Current studies
collecting multiple patient samples to more closely investi-
gate the correlation of CCL2 upregulation in prostate cancer
bone metastases are underway. Analysis of CCR2 re-
ceptor expression using the ONCOMINE database, which
contains publicly available gene expression sets comparing
expression data between benign prostatic hyperplasia
(n = 23), localized prostate cancer (n = 64), and metastatic
prostate cancer (n = 25), identified a statistically significant
(P < .01) increase in CCR2 mRNA expression, which cor-
relates with disease progression [22]. Taken together,
these data suggest that CCL2 produced by the bone
Figure 4. CCL2 induces Akt phosphorylation in prostate cancer cells. PC-3 (A) and VCaP (C) were treated with CCL2 (100 ng/ml) for 0 to 30 minutes, and Akt
phosphorylation was determined by Western blot analysis. PC-3 (B) and VCaP (D) were treated with increasing concentrations of CCL2 (0–100 ng/ml) for
30 minutes, and Akt phosphorylation was determined. Total Akt was visualized and used for normalization of densitometric analyses. (E) GSK3a/ and (F) p70-S6
kinase, two downstream targets of Akt, were analyzed in PC-3 cells stimulated with CCL2 (100 ng/ml).
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microenvironment inducesCCR2 receptor activation on pros-
tate cancer epithelial cells and may promote prostate cancer
growth and metastasis.
CCL2 belongs to a family of cytokines that is known to
promote the migration of monocytes and macrophages to
sites of inflammation. Recently, a role of CCL2 in regulating
the migration and proliferation of cancer epithelial cells
has been shown in breast cancer and multiple myeloma
[5,7,23,24]. Upregulation of cytokines and chemokines at the
site of a secondary lesion has been postulated to play an im-
portant role in ‘‘homing’’ and tumor formation. For example,
SDF-1/CXCR4 has recently been shown to exert a predomi-
nant role in regulating prostate cancer cell metastasis to the
bone [4]. In the data presented here, we demonstrate the
ability of CCL2 to stimulate prostate cancer cell migration and
proliferation in a dose-dependent manner. Additionally, the
predominant source of CCL2 in the bone microenvironment
appears to be the bone marrow endothelial cells (Figure 2).
CCL2 is known to be synthesized by the vascular endothelium
as a mechanism to recruit monocytes and macrophages to
sites of vascular injury. Our initial data have demonstrated
that bone marrow endothelial cells secrete significantly higher
levels of CCL2 compared to two vascular endothelial cell lines
in culture (HAECs and HDMVECs; Figure 2B). The signifi-
cance of the elevated secretion of CCL2 by bone marrow
endothelial cells is unclear; however, we hypothesize that the
elevated CCL2 levels released by the bone marrow endo-
thelium may be an important component of the bone micro-
environment that influences the predominance of prostate
cancer bone metastases.
Figure 5. CCL2 induces PC-3 and VCaP cell proliferation through a PI3
kinase/Akt –dependent mechanism. PC-3 (A) and VCaP (B) cells were plated
in a 96-well plate and stimulated with increasing concentrations of hrCCL2
(1–100 ng/ml) for 24 to 96 hours (solid lines, open symbols). LY294002 (PI3
kinase inhibitor) was added at 1 M (dashed lines, solid symbols) and com-
pared to the vehicle-treated control (solid line, solid symbol). LY294002 alone
(gray line) did not affect PC-3 or VCaP cell proliferation directly. Data are
presented as mean ± SD.
Table 2. Differential Expression of the CCL2 Receptor CCR2 in a Panel of
Prostate Cancer Cell Lines.
GAPDH Ct CCR2 Ct n 2
DCt P
Average SD Average SD
RWPE-1 15.945 0.057 28.412 0.018 3 1.77E04 –
PC-3 17.743 0.031 27.099 0.071 3 3.39E04 < .01
VCaP 16.450 0.039 27.154 0.054 3 6.00E04 < .001
DU145 17.218 0.091 31.235 0.118 3 6.03E05 –
LNCaP 18.484 0.740 32.541 0.871 3 5.87E05 –
C4-2B 16.317 0.197 28.523 0.652 3 2.12E04 < .05
CCR2 expression was calculated relative to the endogenous control
housekeeping gene GAPDH using the DCt method [relative expression =
2DCt, where DCt = Ct(CCR2)  Ct(GAPDH)]. Data represent the mean of three
experiments performed in quadruplicate (n = 3; mean ± SD).
Figure 6. CCL2 induces actin rearrangement and lamellipodial formation in
PC-3 cells. Unstimulated PC-3 cells (A) were compared to PC-3 cells that
were stimulated with CCL2 (100 ng/ml) (B) in the presence of a neutralizing
CCL2 antibody (4 g/ml) (C) or SDF-1 (200 ng/ml) (D) as a positive control.
The nucleus was stained with DAPI (blue), and actin was visualized with
rhodamine phallodin (red).
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Currently, the only study to have addressed the role of
CCL2 in prostate cancer focused on CCL2 expression in
prostate epithelial cells and stromal cells during benign pros-
tatic hyperplasia and localized prostatic adenocarcinoma.
CCL2 was shown to be expressed by smooth muscle cells
in the prostate gland surrounding the epithelial cells and in
benign epithelial cells. CCL2 expression was reported to
be less in the cancerous epithelial cells of localized prostate
cancer [25]. The data presented here suggest that the
function of CCL2 in prostate cancer pathogenesis may be
localized to the metastatic process and may be an important
mechanism in the development of bone metastases of pros-
tate cancer cells. Here we demonstrate the ability of HBME
cells to secrete significantly higher levels of CCL2 compared
to HAECs and HDMVECs (Figure 2B). We recognize that
monocytes/macrophages and osteoclasts are known to se-
crete CCL2; to date, it remains unclear how these cells
contribute to the CCL2-rich bone microenvironment. The
data presented here suggest that the bone marrow endo-
thelium contributes to the overall elevated levels of CCL2 in
the tumor–bone microenvironment and may promote a va-
riety of functions, including tumor cell migration and extra-
vasation, tumor cell growth, macrophage infiltration and
differentiation, and osteoclast activation. Furthermore, we
have demonstrated CCL2 to act as a chemoattractant for
bone-derived prostate cancer epithelial cells and to regulate
their migratory properties in a dose-dependent fashion
(Figure 3). Additionally, we have demonstrated that CCL2
stimulates the proliferation of prostate cancer cells by a
LY294002-sensitive mechanism that is consistent with PI3
kinase–mediated mechanism. Furthermore, stimulation with
CCL2 induces Akt phosphorylation with further downstream
activation of the p70-S6 kinase (Figure 4). Activation of p70-
S6 kinase has been shown to regulate changes in the actin
cytoskeleton [19] and, thus, may play a role in the enhanced
migratory phenotype of prostate cancer cells when stimulated
with CCL2. Furthermore, the p85-S6 kinase is a second iso-
form of the p70-S6 kinase, which contains a nuclear locali-
zation signal in the N-terminus. Stimulation of PC-3 cells
resulted in the activation of p85-S6 kinase, which may be
important in regulating portions of the nuclear matrix. The
chemokine family has been postulated to play a significant
role in the tumorigenesis and metastasis of several human
cancers [6,26]. Recently, evidence has suggested that CCR2,
the high-affinity receptor for CCL2, is linked to the actin
cytoskeleton through interactions with FROUNT [27,28]. It
will be important to determine if alternative CCL2 receptors
interact with the cytoskeleton to regulate the migration and
proliferation of prostate cancer cells. Further analysis of CCL2
is essential to fully understand the involvement of CCL2 in
the pathogenesis of prostate cancer.
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